A 68-year-old Illinois woman, diagnosed with COVID-19 (CCP Virus), is finally receiving ivermectin treatment after her daughter sued the hospital where she had been hospitalized for a month on a ventilator to have it administered, the Chicago Tribune reported.
Nurije Fype, who has been a patient at Elmhurst Hospital in Illinois since 7 April and was placed on a ventilator on 28 April, is now in a coma.
According to reports, Fype’s daughter Desareta, who was granted temporary guardianship of her mother, read a story about a woman in upstate New York who recovered from Covid after receiving ivermectin and went to court to ensure that her mother received the treatment.
The media outlet further reported that Elmhurst Hospital’s lawyer told a court hearing on Tuesday, 1 June, that an outside doctor was credentialed to work at the hospital to administer ivermectin to Nurije Fype after hospital officials said they could not find a doctor affiliated with the hospital to administer the ivermectin.
According to the Daily Herald, the judge said at Tuesday’s hearing: “Now let’s hope the good Lord allows the medication to work.”
He also reported that Ms. Fype’s lawyers cited arguments from “Covid Frontline Critical Care Alliance” that ivermectin has antiviral and anti-inflammatory benefits that help people infected with the Wuhan coronavirus.
Desareta herself responded in a tweet to a person who asked how her mother was doing after receiving treatment with ivermectin, saying that her mother is “Slowly heading in a good direction!.”
The Food and Drug Administration (FDA) denies approval for use as a treatment against the CCP Virus, claiming there is not enough data to recommend it, even though the popular antiparasitic has been highly effective in COVID-19 positive patients in several places.
Some of the countries that have been in the news lately for the encouraging results they are having with ivermectin are India, Mexico, and Ecuador.
As reported by The BL a few days ago, in Delhi, where the medication was started on 20 April, following the guidelines of the Indian Institute of Medical Sciences (AIIMS), cases dropped from 28,395 to just 2,260 on 22 May. This represents a staggering 92% drop. Similarly, cases in Uttar Pradesh have fallen from 37,944 on April 24 to 5,964 on May 22, corresponding to a drop of 84 percent.
Another resounding case was announced by the Mexico City government on 14 May, when it reported excellent results from a study that tested the use of ivermectin in people infected with the CCP Virus. It showed a 52-76% reduction in the likelihood of needing hospitalization.
But despite the fact that in the US and most other countries, government agencies and doctors remain sceptical about the use of this inexpensive and affordable drug, and are still only listening to the recommendations of the FDA and even the WHO that only promote the distribution of the experimental vaccine, a group of high-profile doctors and scientists have spoken out in favour of it.
One of them is leading medical scientist Dr. Pierre Kory of the Front Line Critical Care Alliance COVID-19, who charged that the WHO’s suppression of the use of ivermectin against the coronavirus would have caused the loss of nearly “half a million lives.”
For Kory, the team of scientists combating the use of ivermectin, in the service of the WHO, committed many irregularities in considering research reports, omitting and hiding data to twist them to suit their economic aspirations.
Ivermectin was discovered in the 1960s by Satoshi Omura, a microbiologist at the Kitasato Institute in Tokyo, and the American biologist and parasitologist William Campbell. After several investigations to optimize its biological activity and safety, it proved to be a potent and effective anti-parasitic against a wide range of parasites.
Later, Australian researchers found that ivermectin also exerts potent antiviral effects against two viruses that cause life-threatening human diseases; human immunodeficiency virus-1 (HIV-1) and dengue virus (DENV). It was also shown to limit infection by viral pathogens such as the Venezuelan equine encephalitis virus and influenza virus.
It appears that ivermectin shares similarities with hydroxychloroquine, not only in the sense that both drugs are very inexpensive, widely available, and have been used to treat other diseases before the emergence of CCHV, proving to be safe and effective but also in the fact that they represent a counterfactual to the economic interests of the big pharmaceutical industry.